85-66-5Cn1c2cccc(=O)c-2nc2ccccc21YNCMLFHHXWETLD-UHFFFAOYSA-Npyocyanine has been reported in Pseudomonas aeruginosa with data available.
85-66-5DTXSID9041108CHEMBL2289232Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P264+P265, P270, P280, P301+P317, P305+P354+P338, P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 39 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
DescriptionPyocyanine (85-66-5), a redox-active phenazine produced byP. aeruginosaand other pathogens, is an electron receptor, which stimulates redox cycling in bacteria as well as in a variety of human cell lines. It enhances oxidative metabolism, which increases the formation of intracellular reactive oxygen species (ROS) via reduction of NADPH. Pyocyanine accelerates neutrophil apoptosisin vitro. Pyocyanine production byP. aeruginosasuppresses the acute inflammatory response by pathogen-driven acceleration of neutrophil apoptosis and associated reduction of local inflammation.
UsesPyocyanin has been used:To disable the ability of forkhead box A2 (FOXA2) to regulate goblet cell hyperplasia and metaplasia (GCHM) and mucin expression.To activate nuclear factor (erythroid-derived 2)-like 2 (NRF2) through the reactive oxygen species (ROS)-inducible epidermal growth factor receptor (EGFR)-phosphoinositide 3-kinase (PI3K) cellular signal transduction pathway and its downstream effectors.To stimulate Pseudomonas aeruginosa PAO1 cell line adhesion and invasion in human lung carcinoma A549 cells via reactive oxygen species (ROS) production.
UsesPyocyanin is an antibiotic accelerator of neutrophil apoptosis.
General DescriptionPyocyanin is a secondary metabolite, which is produced by Pseudomonas aeruginosa.
No reaction records under the current filter.
Loading…